| First Author | Ciuclan L | Year | 2013 |
| Journal | Am J Pathol | Volume | 183 |
| Issue | 5 | Pages | 1461-73 |
| PubMed ID | 24160323 | Mgi Jnum | J:202740 |
| Mgi Id | MGI:5521400 | Doi | 10.1016/j.ajpath.2013.07.017 |
| Citation | Ciuclan L, et al. (2013) Treatment with Anti-Gremlin 1 Antibody Ameliorates Chronic Hypoxia/SU5416-Induced Pulmonary Arterial Hypertension in Mice. Am J Pathol 183(5):1461-73 |
| abstractText | The expression of the bone morphogenetic protein antagonist, Gremlin 1, was recently shown to be increased in the lungs of pulmonary arterial hypertension patients, and in response to hypoxia. Gremlin 1 released from the vascular endothelium may inhibit endogenous bone morphogenetic protein signaling and contribute to the development of pulmonary arterial hypertension. Here, we investigate the impact of Gremlin 1 inhibition in disease after exposure to chronic hypoxia/SU5416 in mice. We investigated the effects of an anti-Gremlin 1 monoclonal antibody in the chronic hypoxia/SU5416 murine model of pulmonary arterial hypertension. Chronic hypoxic/SU5416 exposure of mice induced upregulation of Gremlin 1 mRNA in lung and right ventricle tissue compared with normoxic controls. Prophylactic treatment with an anti-Gremlin 1 neutralizing mAb reduced the hypoxic/SU5416-dependent increase in pulmonary vascular remodeling and right ventricular hypertrophy. Importantly, therapeutic treatment with an anti-Gremlin 1 antibody also reduced pulmonary vascular remodeling and right ventricular hypertrophy indicating a role for Gremlin 1 in the progression of the disease. We conclude that Gremlin 1 plays a role in the development and progression of pulmonary arterial hypertension in the murine hypoxia/SU5416 model, and that Gremlin 1 is a potential therapeutic target for pulmonary arterial hypertension. |
